Search

Your search keyword '"Thomas, Roman K."' showing total 815 results

Search Constraints

Start Over You searched for: Author "Thomas, Roman K." Remove constraint Author: "Thomas, Roman K."
815 results on '"Thomas, Roman K."'

Search Results

1. Evolutionary trajectories of small cell lung cancer under therapy

2. CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 HeterodimerizationCD74-NRG1 Gene Fusion as a Bona Fide Oncogene

3. Somatic rearrangements causing oncogenic ectodomain deletions of FGFR1 in squamous cell lung cancer

5. Pulmonary cancers across different histotypes share hybrid tuft cell/ionocyte-like molecular features and potentially druggable vulnerabilities

6. Chromothripsis followed by circular recombination drives oncogene amplification in human cancer

7. Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors.

8. A Tuft Cell–Like Signature Is Highly Prevalent in Thymic Squamous Cell Carcinoma and Delineates New Molecular Subsets Among the Major Lung Cancer Histotypes

9. Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors

10. Correction to: Identification of TAZ as the essential molecular switch in orchestrating SCLC phenotypic transition and metastasis

11. A mechanistic classification of clinical phenotypes in neuroblastoma

12. MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I

13. Ferroptosis response segregates small cell lung cancer (SCLC) neuroendocrine subtypes

14. Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer

16. Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer

17. Comprehensive genomic profiles of small cell lung cancer

18. K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways

19. Table S7 from Characterizing Evolutionary Dynamics Reveals Strategies to Exhaust the Spectrum of Subclonal Resistance in EGFR-Mutant Lung Cancer

20. Supplementary Data from Characterizing Evolutionary Dynamics Reveals Strategies to Exhaust the Spectrum of Subclonal Resistance in EGFR-Mutant Lung Cancer

21. Data from Characterizing Evolutionary Dynamics Reveals Strategies to Exhaust the Spectrum of Subclonal Resistance in EGFR-Mutant Lung Cancer

25. Epidermal Growth Factor Receptor Activation in Glioblastoma through Novel Missense Mutations in the Extracellular Domain.

26. Table S2 from Distinct Genetically Determined Origins of Myd88/BCL2-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies

27. Supplementary Figures S1 to S12 from Distinct Genetically Determined Origins of Myd88/BCL2-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies

28. Data from Distinct Genetically Determined Origins of Myd88/BCL2-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies

29. Supplementary Figure from CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization

30. Data from CD74–NRG1 Fusions in Lung Adenocarcinoma

31. Supplementary Data from CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization

32. Data from Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer

33. Data from Cell-Autonomous and Non–Cell-Autonomous Mechanisms of Transformation by Amplified FGFR1 in Lung Cancer

34. Interview with Dr. Meyerson from Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer

35. Supplementary text from Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts

36. Supplementary Tables from CD74–NRG1 Fusions in Lung Adenocarcinoma

37. Supplementary Methods and Legends from Cell-Autonomous and Non–Cell-Autonomous Mechanisms of Transformation by Amplified FGFR1 in Lung Cancer

38. Data from Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts

39. Supplementary Figure Legends 1-7 from Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer

40. Supplementary Figures 1-7 from Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer

41. Supplementary Tables S3-S8 from Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts

42. Supplementary Table 1 from Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer

43. Supplementary Figures S1-S14 from Cell-Autonomous and Non–Cell-Autonomous Mechanisms of Transformation by Amplified FGFR1 in Lung Cancer

44. Supplementary Figures 1-11 from Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts

45. Supplementary Figures from CD74–NRG1 Fusions in Lung Adenocarcinoma

46. Supplementary Figure 3 from Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors

47. Data from ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors

48. Supplementary Data from Blood-Based Gene Expression Signatures in Non–Small Cell Lung Cancer

49. Supplementary Table S2 from Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer

50. Supplementary Figure Legends 1-7 from Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants

Catalog

Books, media, physical & digital resources